Lonza Awarded Commercial Manufacturing Agreement with Altus Pharmaceuticals
Lonza Group Ltd announced that an agreement with Altus Pharmaceuticals Inc. has been signed, whereby Lonza is granted long term manufacturing rights for Altus' ALTU-135 drug substances. All related production will be conducted in Lonza's FDA registered facility in Kouím, Czech Republic. The scope of manufacturing agreement includes microbial fermentation, process optimization, technical and regulatory support. In conjunction with the project, Lonza plans to enhance its down-stream processing competencies and hire additional skilled employees for the Kouím facility.
ALTU-135 was developed by Altus and is an orally administered enzyme replacement therapy for patients with pancreatic insufficiency. Altus plans initiating Phase III clinical trial in 2007, and preparations with Lonza are underway for a successful commercial launch.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.